148 related articles for article (PubMed ID: 32889849)
21. HIV-negative plasmablastic lymphoma: not in the mouth.
Castillo JJ; Winer ES; Stachurski D; Perez K; Jabbour M; Milani C; Colvin GA; Butera JN
Clin Lymphoma Myeloma Leuk; 2011 Apr; 11(2):185-9. PubMed ID: 21575922
[TBL] [Abstract][Full Text] [Related]
22. Impact of highly active antiretroviral therapy in the development and remission of oral plasmablastic lymphoma.
Wagner VP; Ortiz L; da Silva HP; Meurer L; da Cunha Filho JJ; Martins MA; Martins MD
Indian J Dent Res; 2016; 27(5):559-562. PubMed ID: 27966518
[TBL] [Abstract][Full Text] [Related]
23. Transformation to plasmablastic lymphoma in CLL upon ibrutinib treatment.
Marvyin K; Tjønnfjord EB; Breland UM; Tjønnfjord GE
BMJ Case Rep; 2020 Sep; 13(9):. PubMed ID: 32994268
[TBL] [Abstract][Full Text] [Related]
24. Durable complete remission with combination chemotherapy and bortezomib in HIV-associated plasmablastic lymphoma.
Arora N; Gupta A; Sadeghi N
BMJ Case Rep; 2017 Oct; 2017():. PubMed ID: 28993364
[TBL] [Abstract][Full Text] [Related]
25. Prognostic factors in chemotherapy-treated patients with HIV-associated Plasmablastic lymphoma.
Castillo JJ; Winer ES; Stachurski D; Perez K; Jabbour M; Milani C; Colvin G; Butera JN
Oncologist; 2010; 15(3):293-9. PubMed ID: 20167839
[TBL] [Abstract][Full Text] [Related]
26. Unusual presentation of gastric plasmablastic lymphoma in HIV-negative patient.
Mihaljevic BS; Todorovic MR; Andjelic BM; Antic DA; Perunicic Jovanovic MD
Med Oncol; 2012 Jun; 29(2):1186-9. PubMed ID: 21476144
[TBL] [Abstract][Full Text] [Related]
27. Plasmablastic lymphoma: an atypical cutaneous presentation of a rare entity.
Mota F; Mesquita B; Carvalho S; Coelho A; Velho G; Lima M; Selores M
Dermatol Online J; 2016 May; 22(5):. PubMed ID: 27617520
[TBL] [Abstract][Full Text] [Related]
28. Stage, age, and EBV status impact outcomes of plasmablastic lymphoma patients: a clinicopathologic analysis of 61 patients.
Loghavi S; Alayed K; Aladily TN; Zuo Z; Ng SB; Tang G; Hu S; Yin CC; Miranda RN; Medeiros LJ; Khoury JD
J Hematol Oncol; 2015 Jun; 8():65. PubMed ID: 26055271
[TBL] [Abstract][Full Text] [Related]
29. Extraoral plasmablastic lymphomas in a high human immunodeficiency virus endemic area.
Meer S; Perner Y; McAlpine ED; Willem P
Histopathology; 2020 Jan; 76(2):212-221. PubMed ID: 31361906
[TBL] [Abstract][Full Text] [Related]
30. Impact of concomitant antiblastic chemotherapy and highly active antiretroviral therapy on human immunodeficiency virus (HIV) viremia and genotyping in HIV-infected patients with non-Hodgkin lymphoma.
Simonelli C; Zanussi S; Cinelli R; Dal Maso L; Di Gennaro G; D'Andrea M; Nasti G; Spina M; Vaccher E; De Paoli P; Tirelli U
Clin Infect Dis; 2003 Sep; 37(6):820-7. PubMed ID: 12955644
[TBL] [Abstract][Full Text] [Related]
31. Bortezomib in combination with infusional dose-adjusted EPOCH for the treatment of plasmablastic lymphoma.
Castillo JJ; Reagan JL; Sikov WM; Winer ES
Br J Haematol; 2015 May; 169(3):352-5. PubMed ID: 25612847
[TBL] [Abstract][Full Text] [Related]
32. Large cell lymphoma: correlation of HIV status and prognosis with differentiation profiles assessed by immunophenotyping.
Pather S; Mohamed Z; McLeod H; Pillay K
Pathol Oncol Res; 2013 Oct; 19(4):695-705. PubMed ID: 23670212
[TBL] [Abstract][Full Text] [Related]
33. [Primary breast lymphoma--a report of 27 cases with literature review].
Cao YB; Wang SS; Huang HQ; Xu GC; He YJ; Guan ZZ; Lin TY
Ai Zheng; 2007 Jan; 26(1):84-9. PubMed ID: 17222374
[TBL] [Abstract][Full Text] [Related]
34. Pediatric plasmablastic lymphoma: a clinicopathologic study.
Vaubell JI; Sing Y; Ramburan A; Sewram V; Thejpal R; Rapiti N; Ramdial PK
Int J Surg Pathol; 2014 Oct; 22(7):607-16. PubMed ID: 24771257
[TBL] [Abstract][Full Text] [Related]
35. Plasmablastic lymphoma achieving sustained remission with antiretroviral therapy alone.
Atallah-Yunes SA; Murphy D; Abdelmalak R; Mantle L; Ali SS
Eur J Haematol; 2019 Dec; 103(6):620-622. PubMed ID: 31505061
[TBL] [Abstract][Full Text] [Related]
36. Oral plasmablastic lymphoma: A case report.
Zizzo M; Zanelli M; Martiniani R; Sanguedolce F; De Marco L; Martino G; Parente P; Annessi V; Manzini L; Ascani S
Medicine (Baltimore); 2020 Sep; 99(39):e22335. PubMed ID: 32991445
[TBL] [Abstract][Full Text] [Related]
37. Highly effective treatment of acquired immunodeficiency syndrome-related lymphoma with dose-adjusted EPOCH: impact of antiretroviral therapy suspension and tumor biology.
Little RF; Pittaluga S; Grant N; Steinberg SM; Kavlick MF; Mitsuya H; Franchini G; Gutierrez M; Raffeld M; Jaffe ES; Shearer G; Yarchoan R; Wilson WH
Blood; 2003 Jun; 101(12):4653-9. PubMed ID: 12609827
[TBL] [Abstract][Full Text] [Related]
38. Impact of highly active antiretroviral therapy in the treatment of HIV-infected patients with systemic non-Hodgkin's lymphoma.
Baiocchi OC; Colleoni GW; Navajas EV; Duarte LC; Alves AC; Andrade AL; Kerbauy J; Oliveira JS
Acta Oncol; 2002; 41(2):192-6. PubMed ID: 12102166
[TBL] [Abstract][Full Text] [Related]
39. A tip of the iceberg: Disseminated plasmablastic lymphoma, diagnosed from a local oral lesion.
Ke YL; Hsiao HH; Cho SF; Wu CC
Kaohsiung J Med Sci; 2021 Apr; 37(4):346-347. PubMed ID: 33340392
[No Abstract] [Full Text] [Related]
40. Disseminated plasmablastic lymphoma.
Sharma R; Abdou S; Plymyer MR; Rohatgi C
J Am Coll Surg; 2004 Oct; 199(4):654-5. PubMed ID: 15454154
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
